Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of nivolumab ± ipilimumab in virus-positive and virus-negative solid tumors
jRCT2080222984Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in gastric adenocarcinoma, Esophagogastric Cancer, nasopharyngeal carcinoma (NPC) and 7 more (2 arms), sponsored by Ono Pharmaceutical. Started Oct 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
gastric adenocarcinomaEsophagogastric Cancernasopharyngeal carcinoma (NPC)cervical squamous cell carcinoma (CSCC)vaginal squamous cell carcinoma (SCCV)
Beyond the preview
Go deeper on jRCT2080222984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222984.